acute myeloid leukemia

  • May 30, 2024  

    How Would an Expert Manage His Own Acute Myelogenous Leukemia: an Update

    With: Adam Asch, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Previously, our Curious Dr. George asked leukemia expert Adam Asch, MD, how he would handle his own hypothetical case of acute myelogenous leukemia (AML). Now, Dr. Asch provides an updated answer, highlighting the new option of clinical trials offering novel targeted therapies for some… Read more »

  • October 24, 2023  

    How Would an Expert Manage His Own Acute Myelogenous Leukemia?

    With: Adam Asch, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks leukemia expert Adam Asch, MD, how he would handle his own case of acute myelogenous leukemia. Dr. Asch is Professor of Medicine and Nancy Johnson Records Chair of Oncology at the University of Oklahoma College of Medicine. Curious… Read more »

  • July 13, 2022  

    Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022 Bookmark

    George Lundberg, MD

    Written for oncology healthcare professionals, this article from the ASCO Educational Book covers targeted therapies and immunotherapies that are now available to improve the prospects of people with acute myeloid leukemia.

    .

  • January 31, 2022  

    NCCN Guidelines for Patients: Acute Myeloid Leukemia Bookmark

    George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for acute myeloid leukemia.

    .

  • March 16, 2021  

    Acute Myeloid Leukemia (AML)—An Overview Bookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic update with treatment options for all stages of acute myeloid leukemia is comprehensive and clear. (Free registration required, written with a physician audience in mind.)

    .

  • October 10, 2020  

    NCCN Guidelines for Patients: Acute Myeloid Leukemia Bookmark

    George Lundberg, MD

    PDF from the National Comprehensive Cancer Network curated by Contributing Editor George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) has issued a 2020 edition of its Guidelines for Patients about acute myeloid leukemia.

    Go to full document published by the NCCN.

    .

  • October 8, 2020  

    Oral Azacitidine Wins FDA Approval for AML Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

    .

  • November 12, 2019  

    ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A clinical trial showed substantial benefits of progression-free survival and overall survival for patients with a particular form of acute myeloid leukemia when treated by gilteritinib versus chemotherapy. However, the disease was still fatal.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 17, 2019  

    Acute Myeloid Leukemia (AML)—An Overview Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Acute myeloid leukemia is a particularly difficult-to-treat form of leukemia. There are standard treatments, but it may be best for a patient to consider a clinical trial early on. This article from Medscape clearly specifies diagnostic and therapeutic options.

    .